Literature DB >> 16580754

One of the most frequent vascular diseases in northeastern of Turkey: Thromboangiitis obliterans or Buerger's disease (experience with 344 cases).

Azman Ates1, Ibrahim Yekeler, Münacettin Ceviz, Bilgehan Erkut, Mustafa Pac, Ahmet Basoglu, Hikmet Kocak.   

Abstract

PURPOSE: This is a retrospective clinical study on adult patients treated surgically for Buerger's disease in our region.
METHODS: In our clinic, 344 patients with Buerger's disease were surgically treated between 1980 and 2004. The major complaints included foot coldness in 312 (90.6%) patients, color changes in 290 (84.3%), rest pain in 160 (46.5%), claudication in 166 (48.2%) and necrotic ulcers in 185 (53.1%). Lumbar sympathectomy was made in 278 (80.2%) patients, thoracic sympathectomy in 7 (2.2%), thoracic and lumbar sympathectomy in 12 (3.6%), lumbar sympathectomy and femoropopliteal or femorotibial bypass in 30 (9%), and femoropopliteal or femorotibial bypass in 17 (5%).
RESULTS: Color changes were improved in 230 (79.3%) patients, food coldness were decreased in 288 (92.3%) and rest pains were improved in 43 (26.8%). Intermittent claudications decreased in 132 of 166 patients. Necrotic ulcers healed in 30 of 185 patients. Amputation was made totally in 155 (53%) patients in 10 years.
CONCLUSIONS: As a nonatherosclerotic, segmental, inflammatory disease, Buerger's disease is casually related to tobacco use. The main goal is to discontinue the use of tobacco. Sympathectomy may be helpful in healing the ulcers and decreasing the symptoms. Vascular reconstruction is rarely possible for patients with Buerger's disease due to segmental involvement and distal nature of the disease.

Entities:  

Mesh:

Year:  2006        PMID: 16580754     DOI: 10.1016/j.ijcard.2005.12.002

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  8 in total

1.  Thoracoscopic cervicothoracic sympathectomy for treatment of upper extremity ischemia.

Authors:  Majid Moini; Mohammad R Rasouli
Journal:  World J Surg       Date:  2008-02       Impact factor: 3.352

Review 2.  Thoracic sympathectomy: a review of current indications.

Authors:  Moshe Hashmonai; Alan E P Cameron; Peter B Licht; Chris Hensman; Christoph H Schick
Journal:  Surg Endosc       Date:  2015-06-27       Impact factor: 4.584

3.  Synergistic contribution of CD14 and HLA loci in the susceptibility to Buerger disease.

Authors:  Zhiyong Chen; Megumi Takahashi; Taeko Naruse; Toshiaki Nakajima; Yi-Wen Chen; Yoshinori Inoue; Isao Ishikawa; Takehisa Iwai; Akinori Kimura
Journal:  Hum Genet       Date:  2007-07-25       Impact factor: 4.132

4.  Buerger's disease as an indicator of socioeconomic development in different societies, a cross-sectional descriptive study in the North-East of Iran.

Authors:  Bahare Fazeli
Journal:  Arch Med Sci       Date:  2010-06-30       Impact factor: 3.318

5.  Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger's Disease): A Multicenter Study of 224 Patients.

Authors:  Alexandre Le Joncour; Simon Soudet; Axelle Dupont; Olivier Espitia; Fabien Koskas; Philippe Cluzel; Pierre Yves Hatron; Joseph Emmerich; Patrice Cacoub; Matthieu Resche-Rigon; Marc Lambert; David Saadoun
Journal:  J Am Heart Assoc       Date:  2018-12-04       Impact factor: 5.501

6.  Thromboangiitis obliterans: Aggressive angioplasty provides a potential solution (randomized pilot study).

Authors:  Mosaad Soliman; Khaled Mowafy; N A Elsaadany; Reem Soliman; Ahmed Elmetwally
Journal:  SAGE Open Med       Date:  2020-06-04

Review 7.  Thromboangiitis obliterans (Buerger's disease).

Authors:  Ignacio J Rivera-Chavarría; José D Brenes-Gutiérrez
Journal:  Ann Med Surg (Lond)       Date:  2016-03-29

8.  The Incidence and Prevalence of Thromboangiitis Obliterans in Taiwan: A Nationwide, Population-based Analysis of Data Collected from 2002 to 2011.

Authors:  Jie-Fu Zheng; Yi-Ming Chen; Der-Yuan Chen; Ching-Heng Lin; Hsin-Hua Chen
Journal:  Clinics (Sao Paulo)       Date:  2016-07       Impact factor: 2.365

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.